Preparing for an influx of cell and gene therapy approvals

There is more momentum than ever to bring cell and gene therapy products to market. But for those to be successful and reach the patients, manufacturers and their partners need to be prepared to address three key challenges.  

Ana Stojanovska, Vice President, Reimbursement & Policy Insights at Xcenda, and Alex Guite, Vice President, Services & Alliances at World Courier, join PharmaPhorum to discuss how to prepare for an influx of cell and gene therapy approvals.